Holen Sie sich die Stockscreener-App
73.92
0.77%
-0.375
Schlusskurs vom Vortag:
$74.30
Offen:
$74.77
24-Stunden-Volumen:
310.93K
Relative Volume:
0.13
Marktkapitalisierung:
$11.77B
Einnahmen:
$705.14M
Nettoeinkommen (Verlust:
$-453.90M
KGV:
-24.32
EPS:
-3.04
Netto-Cashflow:
$-551.29M
1W Leistung:
+1.01%
1M Leistung:
+6.62%
6M Leistung:
+124.92%
1J Leistung:
+90.22%
1-Tages-Spanne:
$73.60
$75.25
1-Wochen-Bereich:
$71.14
$75.49
52-Wochen-Spanne:
$23.95
$75.49
Ionis Pharmaceuticals Inc Stock (IONS) Company Profile
Firmenname
Ionis Pharmaceuticals Inc
Sektor
Branche
Telefon
(760) 931-9200
Adresse
2855 GAZELLE COURT, CARLSBAD, CA
Vergleichen Sie IONS mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
IONS
Ionis Pharmaceuticals Inc
|
73.86 | 12.03B | 705.14M | -453.90M | -551.29M | -3.04 |
|
VRTX
Vertex Pharmaceuticals Inc
|
423.50 | 109.11B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
634.50 | 68.50B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
441.12 | 60.25B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
828.79 | 50.39B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
182.35 | 40.44B | 447.02M | -1.18B | -868.57M | -6.1812 |
Ionis Pharmaceuticals Inc Stock (IONS) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-10-08 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2025-09-26 | Hochstufung | Goldman | Sell → Neutral |
| 2025-09-03 | Hochstufung | BMO Capital Markets | Market Perform → Outperform |
| 2025-07-31 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2025-07-01 | Hochstufung | Barclays | Equal Weight → Overweight |
| 2025-04-07 | Eingeleitet | H.C. Wainwright | Buy |
| 2025-03-31 | Eingeleitet | Redburn Atlantic | Neutral |
| 2024-08-02 | Herabstufung | BMO Capital Markets | Outperform → Market Perform |
| 2024-07-24 | Hochstufung | Leerink Partners | Market Perform → Outperform |
| 2024-07-16 | Fortgesetzt | Jefferies | Buy |
| 2024-06-14 | Hochstufung | Bernstein | Underperform → Mkt Perform |
| 2024-04-10 | Hochstufung | Wolfe Research | Peer Perform → Outperform |
| 2024-01-02 | Hochstufung | BofA Securities | Neutral → Buy |
| 2023-10-23 | Hochstufung | BofA Securities | Underperform → Neutral |
| 2023-09-29 | Eingeleitet | Raymond James | Strong Buy |
| 2023-07-31 | Hochstufung | Citigroup | Neutral → Buy |
| 2023-06-07 | Fortgesetzt | Piper Sandler | Overweight |
| 2023-05-04 | Hochstufung | Citigroup | Sell → Neutral |
| 2023-03-21 | Eingeleitet | Bernstein | Underperform |
| 2022-12-21 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2022-09-09 | Fortgesetzt | Morgan Stanley | Overweight |
| 2022-07-18 | Fortgesetzt | Oppenheimer | Outperform |
| 2022-03-31 | Fortgesetzt | Piper Sandler | Overweight |
| 2022-03-01 | Eingeleitet | Citigroup | Sell |
| 2022-03-01 | Eingeleitet | Guggenheim | Buy |
| 2022-02-01 | Herabstufung | BofA Securities | Buy → Underperform |
| 2021-12-14 | Hochstufung | William Blair | Mkt Perform → Outperform |
| 2021-05-07 | Hochstufung | UBS | Sell → Neutral |
| 2021-03-01 | Hochstufung | Barclays | Underweight → Equal Weight |
| 2020-12-16 | Eingeleitet | UBS | Sell |
| 2020-12-15 | Hochstufung | Cowen | Market Perform → Outperform |
| 2020-09-14 | Fortgesetzt | JP Morgan | Neutral |
| 2020-09-02 | Eingeleitet | The Benchmark Company | Hold |
| 2020-06-01 | Fortgesetzt | Oppenheimer | Outperform |
| 2020-05-13 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2020-03-05 | Eingeleitet | Citigroup | Buy |
| 2019-12-13 | Eingeleitet | Oppenheimer | Outperform |
| 2019-11-13 | Eingeleitet | BofA/Merrill | Buy |
| 2019-11-07 | Herabstufung | Morgan Stanley | Equal-Weight → Underweight |
| 2019-09-10 | Hochstufung | Bernstein | Mkt Perform → Outperform |
| 2018-08-08 | Bestätigt | Stifel | Hold |
| 2018-08-07 | Bestätigt | Stifel | Hold |
| 2018-05-08 | Herabstufung | Evercore ISI | Outperform → In-line |
| 2017-10-06 | Fortgesetzt | Goldman | Sell |
| 2017-08-17 | Eingeleitet | Evercore ISI | Outperform |
| 2017-08-09 | Bestätigt | Stifel | Hold |
| 2017-03-10 | Herabstufung | Goldman | Neutral → Sell |
| 2016-12-28 | Bestätigt | BMO Capital Markets | Outperform |
| 2016-12-27 | Bestätigt | Leerink Partners | Mkt Perform |
Alle ansehen
Ionis Pharmaceuticals Inc Aktie (IONS) Neueste Nachrichten
Why Ionis Pharmaceuticals Inc. stock attracts high net worth investorsWeekly Risk Report & Daily Chart Pattern Signals - newser.com
How Ionis Pharmaceuticals Inc. (ISI) stock compares with tech leadersJuly 2025 Short Interest & Long-Term Growth Plans - newser.com
37,649 Shares in Ionis Pharmaceuticals, Inc. $IONS Bought by Y Intercept Hong Kong Ltd - MarketBeat
How Ionis Pharmaceuticals Inc. stock trades during market volatilityQuarterly Trade Review & Entry and Exit Point Strategies - newser.com
Volatility clustering patterns for Ionis Pharmaceuticals Inc.Earnings Overview Summary & Capital Protection Trade Alerts - newser.com
Is Ionis Pharmaceuticals Inc. (ISI) stock undervalued after correctionGold Moves & Capital Efficient Trading Techniques - newser.com
Will Ionis Pharmaceuticals Inc. (ISI) stock profit from AI boomPortfolio Risk Summary & Growth Focused Entry Point Reports - newser.com
Why Ionis Pharmaceuticals Inc. stock remains on watchlists2025 Investor Takeaways & Real-Time Chart Breakout Alerts - newser.com
Is Ionis Pharmaceuticals Inc. stock poised for growth2025 Market Overview & Weekly Market Pulse Updates - newser.com
Wall Street Zen Downgrades Ionis Pharmaceuticals (NASDAQ:IONS) to Hold - MarketBeat
Can Ionis Pharmaceuticals Inc. stock hit analyst price targetsWeekly Gains Summary & Technical Analysis for Trade Confirmation - newser.com
Earnings Update: Here's Why Analysts Just Lifted Their Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) Price Target To US$81.91 - simplywall.st
US$81.91That's What Analysts Think Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) Is Worth After These Results - Yahoo Finance
Pinnacle Associates Ltd. Sells 113,978 Shares of Ionis Pharmaceuticals, Inc. $IONS - MarketBeat
Can Ionis Pharmaceuticals Inc. stock resist market sell offsWeekly Trade Review & Capital Efficiency Focused Strategies - newser.com
Candlestick signals on Ionis Pharmaceuticals Inc. stock today2025 Top Gainers & Risk Controlled Daily Trade Plans - newser.com
Published on: 2025-10-31 22:00:20 - newser.com
Ionis Pharmaceuticals (NASDAQ:IONS) Price Target Raised to $99.00 - MarketBeat
Ionis Pharmaceuticals (NASDAQ:IONS) Sets New 1-Year High on Earnings Beat - MarketBeat
Royal Bank Of Canada Issues Positive Forecast for Ionis Pharmaceuticals (NASDAQ:IONS) Stock Price - MarketBeat
Ionis Pharmaceuticals (NASDAQ:IONS) Given Strong-Buy Rating at Raymond James Financial - MarketBeat
Ionis Pharmaceuticals (NASDAQ:IONS) Price Target Raised to $90.00 at Needham & Company LLC - MarketBeat
Why ETFs are accumulating Ionis Pharmaceuticals Inc. (ISI) stockAnalyst Upgrade & Safe Entry Zone Tips - newser.com
Will Ionis Pharmaceuticals Inc. stock deliver better than expected guidance2025 Growth vs Value & AI Enhanced Trading Signals - newser.com
Is Ionis Pharmaceuticals Inc. (ISI) stock a fit for income portfoliosTrade Analysis Report & Expert Approved Momentum Ideas - newser.com
Is Ionis Pharmaceuticals Inc. stock ready for breakoutJuly 2025 Opening Moves & Free Weekly Chart Analysis and Trade Guides - newser.com
IQ EQ FUND MANAGEMENT IRELAND Ltd Increases Holdings in Ionis Pharmaceuticals, Inc. $IONS - MarketBeat
What is the fair value estimate for Ionis Pharmaceuticals Inc. (ISI) stock in 2025Quarterly Earnings Report & Low Risk High Reward Trade Ideas - newser.com
Ionis Pharmaceuticals Faces Investor Risks Amid Market Volatility and Milestone Uncertainties - TipRanks
Ionis Pharmaceuticals stock hits 52-week high at $74.42 By Investing.com - Investing.com Philippines
Decoding Ionis Pharmaceuticals Inc (IONS): A Strategic SWOT Insi - GuruFocus
Published on: 2025-10-30 23:08:16 - newser.com
Ionis Pharmaceuticals, Inc. (IONS) Analyst insights, Price targets and Recommendations - Yahoo! Finance UK
TD Cowen Raises Ionis Pharmaceuticals (IONS) Price Target to $99 - GuruFocus
Ionis Pharmaceuticals Inc (IONS) Q3 2025 Earnings Call Highlights: Strong Revenue Growth and ... By GuruFocus - Investing.com Canada
Morgan Stanley Raises Price Target for Ionis Pharmaceuticals (IO - GuruFocus
Ionis Beats Q3 Earnings & Sales Estimates, Raises 2025 Outlook - sharewise.com
Ionis Pharmaceuticals stock hits 52-week high at $74.42 - Investing.com
Ionis Pharmaceuticals Inc (IONS) Q3 2025 Earnings Call Highlight - GuruFocus
Barclays Raises Ionis Pharmaceuticals (IONS) Price Target to $95 - GuruFocus
HC Wainwright Maintains 'Buy' Rating on Ionis Pharmaceuticals (I - GuruFocus
RBC Capital Maintains Outperform Rating on IONS, Raises Price Ta - GuruFocus
Finanzdaten der Ionis Pharmaceuticals Inc-Aktie (IONS)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.21%
0.74%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):